A Secondary Analysis from AZALEA-TIMI 71: Long-acting Factor XI Inhibition and Periprocedural Bleeding

Patel, ESC 2024

Anthos Therapeutics Unveils Additional Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating that the Factor XI Inhibitor Abelacimab was Associated with Remarkably Low Levels of Periprocedural Bleeding in Patients with Atrial Fibrillation

Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition

Current Research in Pharmacology and Drug Discovery

Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke

Investigational Anticoagulant May be Cost Effective

Managed Healthcare Executive

First-Ever Cost-Effectiveness Analysis of a Factor XI Inhibitor Demonstrates that Abelacimab, if Approved, Could Offer Significant Cost Savings as Compared to a Current Standard of Care Anticoagulant

Anthos Therapeutics Announces Appointment of Bill Meury as CEO

Targeting factor XI and factor XIa to prevent thrombosis

Blood

New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding

Wall Street Journal

Biotech Nation: Combatting Blood Clots!!! Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics

Biotech Nation

The AZALEA-TIMI 71 Study and the Future of Factor XI Inhibition: Reflections from the American Heart Association Scientific Congress 2023

European Medical Journal

InnovationRx: A New Blood Thinner On The Horizon

Forbes

Anthos blood thinner bests Xarelto on safety in mid-stage study

Bio Pharma Dive

Factor XI inhibitor for AF drastically reduces bleeding vs. rivaroxaban in phase 2 trial

Healio

AZALEA-TIMI 71-A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared with Open-Label Rivaroxaban in Patients with Atrial Fibrillation

Christian Ruff, AHA 2023

Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review

Reviews in Cardiovascular Medicine

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)

Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023

Regulatory Authorities in China and Japan Approve Clinical Trials for Anthos Therapeutics’ Dual-Acting Factor XI/XIa Inhibitor Abelacimab

Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction

The Oncologist

New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023

New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023

News at XI: moving beyond factor Xa inhibitors

Journal of Thrombosis and Haemostasis

First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants

Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab

Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab

Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer

Biotech Nation: Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics

Biotech Nation

Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention

Anthos Therapeutics Appoints Drew Young as Chief Commercial Officer and Head of Patient Experience

Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial

NPR Tech Nation Radio with CMO Dan Bloomfield, MD, FACC, FAHA

NPR Tech Nation

Atrial Fibrillation Clinical Trial with Novel Dual Activity Factor XI Agent Completes Enrollment

Abelacimab and factor XI inhibition: a novel mechanism for the prevention of venous thromboembolism

CardioPulse

Bleeding Edge: Anthos Pursues a Monthly Anticoagulant

Genetic Engineering and Biotechnology News

Abelacimab for Prevention of Venous Thromboembolism

The New England Journal of Medicine

Factor XI Inhibition to Uncouple Thrombosis From Hemostasis

Journal of the American College of Cardiology

Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine

Single abelacimab dose reduces VTE after knee replacement surgery

Healio

Anthos Therapeutics is Developing a Hemostasis-Sparing Anticoagulant to Reduce the Hazard of Bleeding

BioSpace

FierceBiotech’s 2019 Fierce 15

Fierce Biotech

Blackstone, Novartis found cardiovascular startup with $250M

Fierce Biotech

Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events

Blood